Loss of reactivity of the pulmonary vascular bed in primary pulmonary hypertension

Samet, Philip; Bernstein, William H.

doi:10.1016/0002-8703(63)90034-6

Cited by 25 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Το γεγο νός τοϋτο μαρτυρεί συνύπαρξιν επιπροσθέτου σπασμού των αγγείων. Εις μεταγενέστερα στάδια τής νόσου ή στένωσις των αγγείων είναι εξ ολοκλή ρου οργανική και ή άκετυλοχολίνη είναι ανενεργής 184 .…”

Section: παθολογικη φυσιολογιαunclassified

Πρωτοπαθης Πνευμονικη Υπερτασις: Μετα Συγχρονου Θεωρησεως Της Πνευμονικης Κυκλοφοριας

Μιχαλοπουλοσ¹

View full text Add to dashboard Cite

Section: παθολογικη φυσιολογιαunclassified

Πρωτοπαθης Πνευμονικη Υπερτασις: Μετα Συγχρονου Θεωρησεως Της Πνευμονικης Κυκλοφοριας

Μιχαλοπουλοσ¹

View full text Add to dashboard Cite

The Management of Primary Pulmonary Hypertension

Palevsky

Fishman²

1991

JAMA

View full text Add to dashboard Cite

Primary pulmonary hypertension is a clinical syndrome characterized by pulmonary hypertension in the absence of sufficient underlying cardiac, parenchymal pulmonary, or systemic disease to account for it. The population of patients with primary pulmonary hypertension is a heterogeneous one, both clinically and histologically. As the etiologic mechanisms are unknown, therapy is directed toward the consequences of the pulmonary vascular process. Oxygen supplementation, the use of digoxin and diuretics for symptomatic heart failure, and anticoagulation all may have a role in treating primary pulmonary hypertension, although vasodilator therapy has been the main area of investigation. Screening for vasodilator responsiveness, defining a favorable vasodilator effect, predicting long-term effectiveness, and deciding who to treat have all been controversial. New approaches, such as use of high-dose calcium channel-blocking agents and continuous intravenous infusion of prostacyclin (an investigational agent), have recently been proposed. When medical therapies are exhausted, heart-lung or lung transplantation has increasingly become an option for selected patients.

show abstract

The Cellular Basis of the Pathophysiology and Treatment of Pulmonary Hypertension

Rich

1996

Vascular Endothelium

View full text Add to dashboard Cite

Loss of reactivity of the pulmonary vascular bed in primary pulmonary hypertension

Cited by 25 publications

References 10 publications

Πρωτοπαθης Πνευμονικη Υπερτασις: Μετα Συγχρονου Θεωρησεως Της Πνευμονικης Κυκλοφοριας

Πρωτοπαθης Πνευμονικη Υπερτασις: Μετα Συγχρονου Θεωρησεως Της Πνευμονικης Κυκλοφοριας

The Management of Primary Pulmonary Hypertension

The Cellular Basis of the Pathophysiology and Treatment of Pulmonary Hypertension

Contact Info

Product

Resources

About